Series
Cardiac electrophysiology
Status
Published
Date
Number of report
050
Cardiac pacemakers
Ask the expert
The report presents a summary of reimbursement situation for cardiac pacemakers.
Both single- and dual-chamber pacemakers are considered. Use of pacemakers is considered in complete atrioventricular block and obstructive hypertrophic cardiomyopathy.
Reimbursement analysis covers the following procedures: implantation, replacement and removal of pacemaker.
The only reimbursement within public / statutory health insurance systems is considered.
Report includes essential information about reimbursement and national funding, including:
- Brief overview of reimbursement system for medical devices
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions in indications or scenarios for use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- Austria
- Belgium
- Denmark
- England (UK)
- France
- Germany
- Italy
- Netherlands
- Norway
- Sweden
- Switzerland
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of devices for cardiac pacemakers include:
- Abbott Vascular (Assurity MRI, Endurity MRI)
- Biotronik (Enitra, Effecta, Epyra, Estella, Evia, Edora)
- Boston Scientific (Essentio, Accolade, Ingenio, Advantio, Vitalio)
- Qinming Medical (Qinming)
- MicroPort CRM (Kora, Reply, Esprit)
- Medico S.p.A. (Gea, Hera, Eos, Sophos, Helios, Mythos, Easy Plus)
- Medtronic (Azure, Advisa MRI, Adapta, Micra, Revo MRI SureScan, Sensia, Versa, EnRhythm, EnPulse, Sigma, Kappa)
- Pacetronix (Tiranga, Pinnacle, CHARAK, Pinnacle-R)
- Vitatron (Vitatron)
Table of content is not available at the moment. Report is still ongoing.
26
Jan 2022
On January 14, 2022, the Government of the Russian Federation released a Decree which approved the inclusion of three devices (implantable pulse generator for urinary/fecal incontinence, bioprosthetic aortic valve/xenoprosthesis, and vessels embolization material) in the List of Essential Implantable Medical Devices.
Read more19
Jan 2022
The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in December 2021. More than 15 recommendations were published in relation to the registration, modification of registration conditions, renewal of registration of devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular, orthopedic, ENT devices, as well as medical aids. Except for this, CNEDiMTS published an opinion about transitional coverage (a newly established pathway for reimbursement) for a cardiovascular device.
Read more27
Dec 2021
On December 17, 2021, NHS Digital released HRG4+ Consultation Grouper for 2022/23. This release is used to support the NHS England and Improvement consultation process for the 2022/23 National Tariff Payment System. In general, there are significant changes in base HRG design. A total of 120 new HRGs were created, multiple HRGs were removed, and the grouping logic was updated significantly. This Consultation Grouper will be superseded by the 2022/23 Local Payment Grouper in March 2022, for use from April 01, 2022.
Read more22
Dec 2021
The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 20520 of November 22, 2021, Tuscany Regional Healthcare has published assessments of seventeen medical devices of various therapeutic areas, including devices belonging to neurology, as well as gastrointestinal, urology, cardiovascular, orthopedics, peripheral vascular, and other fields of care.
Read more09
Dec 2021
In November 2021, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (percutaneous implantation of pulmonary artery pressure sensors in chronic heart failure and coronary sinus narrowing device implantation for refractory angina), one new Medical Technologies Guidance (Synergo for non-muscle-invasive bladder cancer), one new Diagnostic Guidance (SeHCAT for diagnosing bile acid diarrhea), and four new Medtech Innovation Briefings (clonoSEQ for minimal residual disease, CerebAir for continuous EEG monitoring, 24/7 EEG SubQ for epilepsy, Paige Prostate for prostate cancer). Also, three new clinical guidelines were published, and six were updated.
Read more